Vidac Pharma weighs Strasbourg expansion through Quest for Health

By AI, Created 4:52 PM UTC, May 18, 2026, /AGP/ – Vidac Pharma is in advanced talks to join Quest for Health, a Strasbourg-based life sciences accelerator, as part of a broader push into continental Europe. The move could add local operations, partnerships and leadership support for the clinical-stage biotech’s oncology programs, with a decision expected by the end of July 2026.

Why it matters: - Vidac Pharma is trying to expand deeper into a major European life sciences corridor. - A Strasbourg base could place the clinical-stage biotech closer to partners, investors, hospitals and research groups. - The move is meant to support Vidac Pharma’s oncology and onco-dermatology development programs.

What happened: - Vidac Pharma Holdings Plc said it is in advanced negotiations to enter Quest for Health, a life sciences and healthcare innovation accelerator headquartered in Strasbourg, France. - The company is also evaluating the establishment of operational and business development activities in the Strasbourg region. - Vidac Pharma expects to decide on the proposed participation in Quest for Health, and the related executive appointment, by the end of July 2026. - Dr. Max Herzberg, Vidac Pharma CEO, said the opportunity could strengthen the company’s presence in European life sciences ecosystems and create room for scientific collaboration and growth.

The details: - Quest for Health is part of a broader innovation ecosystem spanning western Germany and Switzerland. - The accelerator brings together biotechnology companies, pharmaceutical developers, academic institutions, hospitals, investors and research organizations. - More than €220 million has been raised by 65 startups in the last three years. - Seven of those startups are EIC Accelerator laureates. - Vidac Pharma said the Strasbourg initiative is intended to improve access to strategic partnerships, investors and specialized infrastructure. - The company said participation in the ecosystem could support regional visibility and proximity to key European healthcare and innovation stakeholders. - Vidac Pharma said it has started a search for a chief executive officer to lead the proposed Strasbourg operations. - The prospective CEO would oversee local business development, strategic partnerships, operational expansion and stakeholder relations. - Vidac Pharma described the expansion as part of its long-term strategy to build a presence in leading international biotechnology hubs. - The company also said the plan could increase proximity to European capital markets, pharmaceutical partners and innovation-focused institutions. - Vidac Pharma is a clinical-stage biopharmaceutical company focused on first-in-class medicines for oncologic and onco-dermatologic diseases. - The company’s therapeutic candidates are designed to target the hyper-glycolytic tumor microenvironment by acting on the Hexokinase-2 metabolic checkpoint. - Vidac Pharma says that approach is intended to renormalize cellular metabolism and selectively induce programmed cell death without affecting surrounding normal tissue. - VDA-1102, Vidac Pharma’s lead drug candidate, has shown activity in clinical studies in Actinic Keratosis and Cutaneous T-cell Lymphoma. - Vidac Pharma shares trade on Xtra under the symbol T9G. - The company’s ISIN is GB00BM9XQ619 and its WKN is A3DTUQ. - Vidac Pharma posted a LinkedIn page at More information.

Between the lines: - The Strasbourg push suggests Vidac Pharma wants more than a symbolic presence in Europe; it appears to be looking for a practical base for partnerships and business development. - The CEO search signals that the company is preparing for a possible operating footprint before finalizing the broader move. - The focus on Quest for Health also shows Vidac Pharma is targeting a networked ecosystem, not just a real estate location.

What’s next: - Vidac Pharma will continue negotiations and evaluations over the coming weeks. - The company plans to make a final call by the end of July 2026. - Any expansion into Strasbourg would likely be tied to the outcome of the CEO search and the company’s broader European strategy.

The bottom line: - Vidac Pharma is positioning a possible Strasbourg launch as a bridge into Europe’s biotech network, with a decision due by late July and an executive hire already in motion.